Statistics on Biotechnology Use  
Business Sector
Biotechnology indicators by relevance of biotechnology in the company's activity.
Unidades: Specified in each variable

;Total;Main;Secondary;Tool required;
Companies carrying out R&D in Biotechnology;1.444;629;262;553;
% Companies by type of biotechnology used: Genetic Code;30,7;39,9;25,7;22,5;
% Companies by type of biotechnology used: Functional Units;37,6;46,4;39,8;26,5;
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;21,3;26,3;20;16,2;
% Companies by type of biotechnology used: Bioprocesses;50,9;42,3;57;58;
% Companies by type of biotechnology used: Subcellular Organisms;8,1;11,6;5,5;5,2;
% Companies by type of biotechnology used: Bioinformatics;22,6;32,3;21;12,5;
% Companies by type of biotechnology used: Nanobiotechnology;9,8;14,5;10,1;4,4;
% Companies by type of biotechnology used: Other;16,9;18,1;19,5;14,2;
% Companies by final application areas of biotechnology use: Human Health;44,3;65;33,6;25,9;
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;15,8;16,9;18;13,5;
% Companies by final application areas of biotechnology use: Food Products;30,7;24,8;30,6;37,5;
% Companies by final application areas of biotechnology use: Agriculture and Forestry;24,9;21,3;28,7;27,3;
% Companies by final application areas of biotechnology use: Environment;16,9;17,9;20,5;14,2;
% Companies by final application areas of biotechnology use: Industry;12,6;13,1;15,9;10,4;
R&D personnel in Biotechnology (PP);17.743;8.842;3.407;5.494;
R&D personnel in Biotechnology (PP): Research personnel;9.445;5.239;1.814;2.392;
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;8.298;3.603;1.594;3.101;
R&D personnel in Biotechnology (PP). Women;9.907;5.154;1.970;2.782;
R&D personnel in Biotechnology (PP). Women: Research personnel;5.104;2.942;1.011;1.151;
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;4.802;2.212;959;1.632;
R&D personnel in Biotechnology (FTE);12.993,4;7.060,1;2.147,6;3.785,7;
R&D personnel in Biotechnology (FTE): Research personnel;7.069,9;4.263,3;1.145,5;1.661,1;
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;5.923,6;2.796,8;1.002,1;2.124,7;
R&D personnel in Biotechnology (FTE). Women;7.471,8;4.169,3;1.295,3;2.007,3;
R&D personnel in Biotechnology (FTE). Women: Research personnel;3.870,1;2.420,4;630,8;819;
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;3.601,6;1.748,9;664,5;1.188,2;
Expenditure on internal R&D in Biotechnology (thousands of euros);1.223.801;670.507;216.401;336.893;
1) By type of expenditure: Current expenditure;1.108.189;604.206;191.555;312.429;
1.1) Labour expenditure of research personnel;360.922;207.759;64.211;88.953;
1.2) Labour expenditure of technical and auxiliary personnel;220.540;104.553;29.638;86.349;
1.3) Other current expenditure;526.727;291.895;97.706;137.126;
2) By type of expenditure: Capital expenditure;115.612;66.301;24.847;24.464;
2.1) Land and buildings;16.843;12.566;799;3.478;
2.2) Equipment and tools;63.527;33.190;12.906;17.431;
2.3) Acquisition of specific R&D software;3.959;2.511;548;900;
2.4) Other R&D-specific IP products;31.284;18.033;10.594;2.656;
1.1) By origin of funds: Own funds;860.603;442.509;148.111;269.983;
1.2) By origin of funds: Funds from the Business sector;128.002;86.860;21.937;19.205;
1.3) By origin of funds: Funds from the Public Administration sector;119.498;69.092;24.659;25.748;
1.4) By origin of funds: Funds from the Higher Education sector;647;620;0;28;
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;12.986;9.058;0;3.927;
1.6) By origin of funds: Funds from the rest of the world;102.065;62.369;21.694;18.002;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);123.396;113.418;5.801;4.177;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;88.985;80.703;4.777;3.505;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;34.412;32.714;1.024;673;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;39,8;50,1;36,6;29,6;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;15,3;13,3;19,2;15,7;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;22,3;24;21,2;20,9;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;12,1;10,8;15,9;11,7;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;17,1;17,6;21,4;14,4;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;17,8;20,3;20,6;13,7;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;16;17,9;18,2;12,8;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;41,4;46,2;41,9;35,8;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;50,2;57,5;50,1;42;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;20,1;21,8;22,6;17;
% Companies with international revenues related to biotechnology activities;22,7;30,6;21,8;14,2;
% Companies representing international revenues related to biotechnology activities;2,1;13,2;0,4;2,2;
% International revenues related to biotechnology activities distributed in: Revenues from the EU;60,6;62,9;52,4;59,7;
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;39,4;37,1;47,6;40,3;
% International revenues related to biotechnology activities by classification: International trade in goods and services;87,8;79,4;98;99,1;
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;10,1;17,6;0;0;
% International revenues related to biotechnology activities by classification: Subsidies from external sources;1,4;1,7;2;0,7;
% International revenues related to biotechnology activities by classification: Other;0,8;1,2;0;0,2;
Notas:
Data referring to all companies that carry out internal R&D in Biotechnology.
 2) ' .'= numeric data equal to zero not resulting from rounding
 3) FTE: Full-Time Equivalence
Fuente: National Statistics Institute